English deutsch Impressum
Sitemap Disclaimer
Company Product Investor Relations Newsroom Careers Contact
 

Strategy
Facts
 Pipeline
 Key figures
 Outlook
Share
Announcements
Financial reports
Presentations
Annual General Meeting
Corporate Governance
Dates & Events
Annual Document
IR Service

Outlook

News flow 2010

REDECTANE®
  • Final Phase III data and report (Q2 2010)
  • Filing with FDA (Q4 2010)
RENCAREX®
  • Announcement of 343 relapses in ARISER trial (2010)
  • Interim analysis for efficacy, basis for filing with EMEA
MESUPRON®
  • Final Phase II data in pancreatic cancer (Q2 2010)
  • Worldwide commercialisation deal
WX-554
  • Complete Phase I healthy volunteer study (H1 2010)

Financial outlook 2010

 
2010
Mio. EUR
2009
Mio. EUR
Sales revenues

N/A
10.0
Other income
1.5 - 2
13.0
Other expenses
26 – 30
25.9
R&D costs
22 – 26
21.8
Cash usage
10 - 14
8.7
Employees
N/A
71


 
© 2006 WILEX AG